#CMSC16 – Genentech’s Ocrelizumab (Ocrevus) a Promising Therapy for Primary Progressive MS; Interview with Lead Researcher
Genentech,Ā a member of the RocheĀ Group, was founded more than 35 years ago and has been focused on a variety of research fields, includingĀ cancer, immunology, neurodegenerative disorders, metabolic diseases, and infectious diseases. Genentech has been committed to discovering and developing new medicines for patients with major diseases of the…